Event Details
Agenda
Abstracts
Event Details
Meeting Resources
This meeting is available via NIH Videocast.
Purpose
The purpose of the Changing the Course of Type 1 Diabetes: The Human Islet Research Network 10-year Anniversary Symposium is to bring together experts in type 1 diabetes (T1D) and investigators outside of the diabetes field to discuss current trends in biomedicine that have the potential to advance T1D research over the next decade. This symposium is open to the public and will focus on emerging concepts and technological advances that will catalyze progress in T1D research in three broad thematic areas: T1D etiology, discovery, and therapies.
Meeting Objectives
- Explore potential roles of different cellular and molecular players in the mechanisms involved in the etiology and/or exacerbation of T1D.
- Highlight current knowledge and opportunities in discovery efforts relevant to T1D.
- Discuss technical developments with potential to influence the study of and development of therapies for T1D.
Background
T1D is a devastating disease resulting from immune destruction of insulin-producing beta cells in the pancreas. T1D patients depend on exogenous insulin for blood glucose control and are at heightened risk for diabetic complications, including cardiovascular and kidney disease, blindness, and the need for limb amputations. Since 2014, the NIDDK-funded Human Islet Research Network (HIRN) has supported collaborative research focused on understanding how beta cells are lost in T1D and on developing innovative strategies to protect or replace functional beta cell mass in diabetic patients. In this symposium, experts in cell biology, physiology, immunology, developmental biology, biochemistry, bioengineering, genetics, and genomics will come together to discuss the contribution of these different fields to advances made in the past 10 years by HIRN and the T1D research community at large and will discuss emerging opportunities to propel T1D research over the next decade and beyond.
Organizing Committee
Kristin Abraham, NIDDK
Rafael Arrojo e Drigo, Vanderbilt University
Mark Atkinson, University of Florida
Olivier Blondel, NIDDK
Leonardo Ferreira, Medical University of South Carolina
Eddie James, Benaroya Research Institute
John Kaddis, City of Hope
Vira Kravets, University of California, San Diego
Karla Leavens, Children’s Hospital of Philadelphia
Wen-Hong Li, The University of Texas Southwestern Medical Center
Jeffrey Millman, Washington University School of Medicine in St. Louis
Joyce Niland, City of Hope
Scott Oakes, The University of Chicago
Audrey Parent, University of California, San Francisco
Layla Rouse, City of Hope
Holger Russ, University of Florida
Desmond Schatz, University of Florida
Cherie Stabler, University of Florida
Abstract Submission Deadline
November 1, 2024
Registration Deadline
January 5, 2025
Agenda
Monday, January 13, 2025
- 8:00 a.m. – 9:00 a.m.
- Arrival, Registration, and Poster Setup
- 9:00 a.m. – 9:25 a.m.
- Meeting Prelude
Griffin P. Rodgers, M.D., MACP, Director, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
John Kaddis, Ph.D., Associate Professor, Department of Diabetes & Cancer Discovery Science, Arthur Riggs Diabetes & Metabolism Research Institute, City of Hope
- 9:25 a.m. – 10:00 a.m.
- Plenary I: The Historical Frontier of Type 1 Diabetes Research
Mark Atkinson, Ph.D., Professor, Departments of Pathology and Pediatrics; Director, University of Florida Diabetes Institute, University of Florida
- 10:00 a.m. – 10:20 a.m.
- Refreshment Break
- 10:20 a.m. – 11:00 a.m.
- Plenary II: A New Dawn in Type 1 Diabetes Research
Audrey Parent, Ph.D., Associate Professor, Diabetes Center, School of Medicine, University of California, San Francisco (UCSF)
Holger Russ, Ph.D., Associate Professor, Department of Pharmacology and Therapeutics, University of Florida
- 11:00 a.m. – 1:00 p.m.
- Lunch/Poster Session I
Pickup pre-ordered lunch (labeled with name)
- 1:00 p.m. – 3:30 p.m.
- Session I: Emerging Approaches and Discoveries in Type 1 Diabetes Research
Moderators: Juan Alvarez, Ph.D., Assistant Professor of Cell and Developmental Biology, University of Pennsylvania Perelman School of Medicine
Rohit Kulkarni, M.D., Ph.D, Professor of Medicine, Harvard Medical School; Diabetes Research & Wellness Foundation Endowed Chair; Senior Investigator and Associate Director (DRC), Joslin Diabetes Center
Engineering Microphysiological Systems to Study Diabetes: Current Progress and Future Directions
Cherie Stabler, Ph.D., Professor and Chair, J. Crayton Pruitt Family & UF Foundation Preeminence Professor, Department of Biomedical Engineering, College of Engineering, University of Florida
The Menage à Trois between Beta Cells, T Cells and Interferons
Roberto Mallone, M.D., Ph.D., Professor, Clinical Immunology, Université Paris Cité, France; Adult Diabetologist, Cochin Hospital, France; Senior Investigator, Indiana Biosciences Research Institute
Restoring Alpha Cell Function in Type 1 Diabetes
Julia Panzer, Ph.D., Research Assistant Professor, Department of Diabetes Immunology, Arthur Riggs Diabetes & Metabolism Research Institute, City of Hope
DYRK1A Inhibitors and Pancreatic Beta Cell Regeneration
Adolfo Garcia-Ocaña, Ph.D., Professor and Chair, Department of Molecular & Cellular Endocrinology, Arthur Riggs Diabetes & Metabolism Research Institute, City of Hope
- 3:30 p.m. – 3:50 p.m.
- Refreshment Break
- 3:50 p.m. – 4:50 p.m.
- Breakout Session I
| Innovative Technologies in Type 1 Diabetes Research |
Room D |
| Moderator: |
Jeffrey Millman, Ph.D., Washington University in Saint Louis |
| Panelists: |
Matthew Ishahak, Ph.D., Washington University in Saint Louis
Emily Sims, M.D., Indiana University School of Medicine
Julie Sneddon, Ph.D., University of California, San Francisco
|
| |
| Debate on Immunomodulation Strategies |
Balcony B |
| Moderator: |
Eddie James, Ph.D., Benaroya Research Institute |
| Panelists: |
Remi Creusot, Ph.D., Columbia University
Sally Kent, Ph.D., UMass Chan Medical School
Everett Meyer, M.D., Ph.D., Stanford University
Qizhi Tang, Ph.D., University of California, San Francisco
|
| |
| Translational Research Collaboration |
Balcony A |
| Moderator: |
Anath Shalev, M.D., the University of Alabama at Birmingham |
| Panelists: |
Juan Dominguez-Bendala, Ph.D., University of Miami
Patrick MacDonald, Ph.D., University of Alberta
Alvin Powers, M.D., Vanderbilt University
Hongjun Wang, Ph.D., Medical University of South Carolina
|
| |
| Career-based: How to Transition and Start a Career in Type 1 Diabetes |
Room C |
| Moderator: |
Alok Joglekar, Ph.D., University of Pittsburgh |
| Panelists: |
Sangeeta Dhawan, Ph.D., City of Hope
Holger Russ, Ph.D., University of Florida
Megan Sykes, M.D., Columbia University
|
| |
| Career-based: Navigating Leadership Opportunities in the Transition to the Mid-Career Phase |
Room A |
| Moderator: |
Amelia Linnemann, Ph.D., Indiana University School of Medicine |
| Panelists: |
Rafael Arrojo e Drigo, Ph.D., Vanderbilt University
Maureen Gannon, Ph.D., Vanderbilt University
Lori Sussel, Ph.D., University of Colorado Anschutz Medical Campus
|
| |
| Discussion and Demonstration of the Pancreas Knowledgebase Program (PanKbase) |
Balcony C |
| Moderators: |
Marcela Brissova, Ph.D., Vanderbilt University
Noël Burrt, Broad Institute
Anna Gloyn, D.Phil., Stanford University
Jie Liu, Ph.D., University of Michigan
|
- 4:50 p.m. – 5:40 p.m.
- Keynote Presentation I: The Vulnerable Period for Islet Autoimmunity
Moderator: Klaus Kaestner, Ph.D., Thomas and Evelyn Suor Butterworth Professor in Genetics; Associate Director of the Diabetes Research Center (DRC), University of Pennsylvania Perelman School of Medicine
Anette-Gabriele Ziegler, M.D., Director of the Institute of Diabetes Research at Helmholtz Munich, German Research Center for Environmental Health; Chair in Diabetes and Gestational DIabetes, Medical Faculty, Technical University Munich, Germany
- 5:40 p.m.
- Adjournment
- 6:30 p.m. – 8:30 p.m.
- Group Dinner
Bethesdan Hotel (pre-registration required)
Tuesday, January 14, 2025
- 8:00 a.m. – 8:30 a.m.
- Arrival, Registration, and Poster Setup
- 8:30 a.m. – 8:50 a.m.
- Introduction and Overview of NIDDK Support and Research Objectives
William Cefalu, M.D., Director, Division of Diabetes, Endocrinology, & Metabolic Diseases, NIDDK
- 8:50 a.m. – 11:10 a.m.
- Session II: Exploring the Cellular and Molecular Etiology of Type 1 Diabetes
Moderators: Romina Bevacqua, Ph.D., Assistant Professor, Diabetes, Obesity and Metabolism Institute, Icahn School of Medicine at Mount Sinai, NY
Lori Sussel, Ph.D., Professor of Pediatrics, University of Colorado Anschutz Medical Campus; Research Director of the Barbara Davis Center for Diabetes
Are we Missing Something? The Small Things Really do Matter in Type 1 Diabetes
Sarah Richardson, Ph.D., Professor of Cellular Biomedicine, University of Exeter, England
The Many Faces of Type 1 Diabetes: Understanding Cell and Tissue Specific Contributions to Biomarker and Treatment Strategies
Carmella Evans-Molina, M.D., Ph.D., Eli Lilly and Company Professor of Pediatric Diabetes at Indiana University (IU) School of Medicine; Director of the IU Center for Diabetes and Metabolic Diseases and the Indiana Diabetes Research Center
Unlocking Early Detection of Type 1 Diabetes through Multiome Profiling and Machine Learning
Golnaz Vahedi, Ph.D., Associate Professor of Genetics, Department of Genetics, University of Pennsylvania Perlman School of Medicine
Beta Cell Protection by Nature
Bart Roep, Ph.D., Professor of Medicine & Professor of Diabetology, Immunopathology and Intervention, Leiden University Medical Center
- 11:10 a.m. – 1:15 p.m.
- Lunch/Poster Session II
Pick up preordered lunch (labeled with name)
- 1:15 p.m. – 2:15 p.m.
- Breakout Session II
| Introduction to Research Groups and Funding Opportunities |
Balcony A |
| Moderator: |
Kristin Abraham, Ph.D., NIDDK |
| Panelists: |
Cassandra Bazile, Ph.D., Breakthrough T1D
John Kaddis, Ph.D., City of Hope
Jay Tinklepaugh, Ph.D., Breakthrough T1D
Monica Westley, Ph.D., The Sugar Science
Ben Williams, Ph.D., The Leona M. and Harry B. Helmsley Charitable Trust
|
| |
| Debate on “Why Beta Cells?” |
Balcony B |
| Moderator: |
Feyza Engin, Ph.D., University of Wisconsin–Madison |
| Panelists: |
Amit Choudhary, Ph.D., Broad Institute
Raghu Mirmira, M.D., Ph.D., The University of Chicago
Bart Roep, Ph.D., Leiden University Medical Center
Jordan Wright, Ph.D., Vanderbilt University
|
| |
| Career-based: Tips on Transitioning for Graduate Students and Postdocs in Academia,
Industry, and Nonprofits |
Room D |
| Moderator: |
Karla Leavens, M.D., Ph.D., Children’s Hospital of Philadelphia |
| Panelists: |
Juan Alvarez, Ph.D., University of Pennsylvania
Romina Bevacqua, Ph.D., Icahn School of Medicine at Mount Sinai
Albert Hwa, Ph.D., NIDDK
Matthias von Herrath, M.D., University of Miami; Novonordisk
Bei Wang, M.D., Ph.D., Regeneron Pharmaceuticals
Matthew Wortham, Ph.D., University of Colorado Anschutz Medical Campus
|
| |
| Career-based: Speed Networking for Early Career Investigators |
Room C |
| Moderators: |
Vira Kravets, Ph.D., University of California, San Diego
Anna Gloyn, D.Phil., Stanford University
Joyce Niland, Ph.D., City of Hope
|
| |
| Demonstration of the Data Portal of the Human Pancreas Analysis Program (PANC-DB) |
Balcony C |
| Moderator: |
Nilanjana Samanta, M.P.H., M.S., University of Pennsylvania |
- 2:15 p.m. – 2:35 p.m.
- Refreshment Break
- 2:35 p.m. – 5:00 p.m.
- Session III: Shaping Therapeutics for Type 1 Diabetes
Moderators: Karla Leavens, M.D., Ph.D., Assistant Professor of Pediatrics, Division of Endocrinology and Diabetes, Children’s Hospital of Philadelphia
Cristina Nostro, Ph.D., Associate Professor, Department of Physiology, University of Toronto; Senior Scientist, McEwen Stem Cell Institute at University Health Network (UHN)
Development of Durable Beta-Cell Replacement Therapy for Type 1 Diabetes
Michael Rickels, M.D., Willard and Rhoda Ware Professor in Diabetes and Metabolic Diseases, Division of Endocrinology, Diabetes & Metabolism, University of Pennsylvania Perelman School of Medicine
Optimizing Stem Cell Derived Beta Cell Functions
Matthias Hebrok, Ph.D., Director, Center for Organoid Systems, Technical University Munich, Germany; Director of the Institute of Diabetes and Organoid Technology, Helmholtz Diabetes Center, Germany
Creating Localized Immune Tolerance in Type 1 Diabetes Using Chimeric Antigen Receptor Regulatory T Cells
Leonardo Ferreira, Ph.D., Assistant Professor, Department of Microbiology and Immunology, Medical University of South Carolina
Engineering Human Islet-specific Tregs for the Treatment of Type 1 Diabetes
Qizhi Tang, Ph.D., Professor of Immunology, School of Medicine, UCSF
- 5:00 p.m. – 5:45 p.m.
- Keynote Presentation II: Transforming Diabetes Research and Care Using Deep Data and Remote Monitoring
Moderator: Anna L. Gloyn, D.Phil., Professor of Pediatrics (Endocrinology) and Genetics at Stanford University
Michael Snyder, Ph.D., Stanford W. Ascherman Professor of Genetics; Director, Stanford Center for Genomics and Personalized Medicine, Stanford University School of Medicine
- 5:45 p.m. – 5:50 p.m.
- Closing Remarks
Rafael Arrojo e Drigo, Ph.D., Assistant Professor, Department of Molecular Physiology and Biophysics, Vanderbilt University
- 5:50 p.m.
- Adjournment
Abstracts
Submission Deadline
November 1, 2024 (5:00 p.m. Eastern Time)
Submitting Abstracts
Attendees of the Changing the Course of Type 1 Diabetes: The Human Islet Research Network 10-year Anniversary Symposium are encouraged to submit a poster abstract for consideration. All abstracts will be reviewed. There is limited space available, so not every submission may result in an invitation to present a poster. Selected posters will emphasize novel and thought-provoking research regarding the future direction of T1D research within the meeting themes of discovery, etiology, and therapy. You must register for the Symposium in order to submit an abstract.
Abstract Review and Selection Criteria
The Abstract Review Committee will consist of experts in the field who will review and rate all submitted abstracts to ensure balanced representation of meeting themes. The review panel will consist of expert reviewers blinded as to the identity of the authors and institutions. Abstracts will be evaluated for poster presentation and considered based on the following criteria:
- Experimental Approach: Introduction, Hypothesis, Approach, Results, Conclusion
- Relevance: Importance in T1D Research
- Innovation & Novelty
- Future: Future Direction of Research
Abstract Submission and Timeline
- Abstract Submission Deadline: November 1, 2024 (5:00 pm Eastern)
- Abstract Notification Date: mid-November 2024
- Poster Session: January 13 & 14, 2025
All abstracts must be submitted via email to John Hare of The Scientific Consulting Group, Inc., with “HIRN Abstract” in the subject line. Abstract submissions should be no longer than 500 words (not including title, name, and affiliation). Please make sure to read the formatting requirements below very carefully. It is extremely important that you follow these specifications.
Formatting Requirements
- The abstract should be an MS Word document, typed and single-spaced using Times New Roman font. Everything but the title should be in normal, 12-point, Times New Roman font.
- The abstract’s title should be Bold, 16-Point, Title Case font and should clearly represent the nature of the investigation. The abstract title should be prefixed with an upper case letter indicating the primary meeting theme being addressed by the poster: “D” for Discovery, “E” for Etiology, or “T” for therapy.
- On the first line after the title, list the authors’ first and last name, degree, affiliation, city, state, and country. The poster presenter should be indicated with an * in the authors list, with the academic level of the presenter provided as a notation at the end of the author list (eg, “*Student, Postdoctoral Fellow, Asst, Assoc or Full Professor)
- Separate multiple authors with a semicolon and underline the primary author’s name (one primary author per abstract).
- Provide 3-5 keywords describing the abstract
- Use one blank line between the title and the body of the abstract and between paragraphs.
- The abstract file name should follow this format: primary author’s LastName_FirstWordOfTitle (e.g., Zucker_Effects).
- Please ensure that your abstract is the correct length (500 words or less) and use 1-inch margins.
- The use of standard abbreviations is desirable (e.g., RBC), as well as standard symbols for units of measure (e.g., kg, g, mg, mL, L, and %). Place nonstandard or unusual abbreviations within parentheses after the full word the first time that it appears. Use numerals to indicate numbers, except to begin sentences. Do not use subtitles (e.g., Methods, Results).
- No figures or tables should be included.
Organize the body of the abstract as follows:
- Experimental Approach: Introduction, Hypothesis, Approach, Results, Conclusion
- Relevance: Importance in T1D Research
- Innovation & Novelty
- Future: Future Direction of Research
Poster boards will be 6’W x 4’H.
.jpg)